Tropomyosin Receptor Kinase (TRK) Signaling
See how Bayer is investigating tropomyosin receptor kinase signaling across the oncology pipeline
Explore the investigational compounds, tumor types, and clinical trials associated with this area of research.
Tropomyosin Receptor Kinase (TRK) Signaling
NTRK genes encode the TRK family of transmembrane receptors, which play important signaling roles in neuronal development and differentiation1,2
NTRK gene fusions can occur via intra- or interchromosomal rearrangements, resulting in the formation of a chimeric gene3
Oncogenic TRK fusion proteins typically form when the kinase domain region of the NTRK gene achieves an in-frame fusion to an unrelated gene3,4
This results in the formation of a constitutively active TRK chimeric protein that is ligand-independent, leading to the uncontrolled activation of downstream pathways and tumor growth3,5
TRK fusion proteins are often mutually exclusive of other known oncogenic genomic alterations and are thus thought to be a primary oncogenic driver3
Bayer is actively engaged in clinical trials relating to TRK inhibition in a wide variety of cancer types
Bayer’s Oncology Pipeline Brochure
Explore a comprehensive overview of Bayer's oncology pipeline, including investigational compounds, clinical trials, and areas of research.
The ongoing clinical trials listed on this website represent a comprehensive overview of Bayer's clinical pipeline in Oncology, including Bayer-sponsored research and collaborative research with academic centers, cooperative groups, and other global institutions.